Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer

Published:2017-10-10 Issue:2 Volume:18 Page:207-213
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Leung Henry W. C.¹,Chan Agnes L. F.²,Muo Chih-Hsin³,Leung John Hang¹

Affiliation:

1. Radiation Oncology, An Nan Hospital, China Medical University, Tainan, Taiwan

2. Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan

3. Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan

Funder

funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2018.1386559

Reference35 articles.

1. American Cancer Society’s. What are the key statistics about breast cancer. Available from: http://www.mbcn.org/incidence-and-incidence-rates/

2. Breast cancer research in Asia: Adopt or adapt Western knowledge?

3. The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan

4. Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer

5. An Economic Evaluation of Adjuvant Trastuzumab Therapy in HER2-Positive Early Breast Cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Evaluation of Neoadjuvant Treatment Strategies for HER2 Positive Breast Cancer: A Systematic Review;International Journal of Cancer Management;2023-12-20

2. Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review;Frontiers in Oncology;2023-11-24

3. The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States;Value in Health Regional Issues;2023-11

4. Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer;Cadernos Saúde Coletiva;2023

5. Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer;The Breast;2022-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3